Takeda Korea, which sold off OTC division & DM division, which was the company's symbol. On the occasion of the 10th anniversary of the corporation's launch, constraints have once again confirmed their commitment to pursuing innovation.

Marking the 240th anniversary of Takeda Pharmaceutical's headquarters and Korea Takeda's 10th Anniversary, 'Takeda has achieved innovative growth for patients,' it held an online press conference.

At this press conference, Take Korea is in line with four key treatment areas: anti-cancer, gastrointestinal disease, nervous system disease, and rare diseases.The general managers of the four major pharmaceutical businesses announced major portfolios and core